{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/key-chemistry-manufacturing-and-controls-strategies-development-cell-and-gene-therapies-0#webpage",
"url": "https://www.fortrea.com/insights/key-chemistry-manufacturing-and-controls-strategies-development-cell-and-gene-therapies-0",
"name": "Key chemistry, manufacturing, and controls strategies for the development of cell and gene therapies",
"description": "Explore this Fortrea white paper focused on advanced chemistry, manufacturing, and controls strategies for the development and commercialization of cell and gene therapies. The white paper examines critical CMC considerations across CGT manufacturing, viral vector production, analytical method development, potency assays, process characterization, GMP manufacturing, quality systems, regulatory readiness, manufacturing scalability, and commercialization planning for advanced therapy medicinal products. It also highlights operational, analytical, and regulatory challenges associated with autologous and allogeneic cell therapies as well as gene therapy programs while outlining integrated CMC development approaches designed to improve product quality, manufacturing efficiency, regulatory compliance, technology transfer, and successful progression from clinical development through commercial manufacturing."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Key chemistry, manufacturing, and controls strategies for the development of cell and gene therapies",
"item": "https://www.fortrea.com/insights/key-chemistry-manufacturing-and-controls-strategies-development-cell-and-gene-therapies-0"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/key-chemistry-manufacturing-and-controls-strategies-development-cell-and-gene-therapies-0#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/key-chemistry-manufacturing-and-controls-strategies-development-cell-and-gene-therapies-0#webpage"
},
"headline": "Advanced CMC Strategies for Cell and Gene Therapies Development and Commercialization | Fortrea White Paper",
"description": "Explore this Fortrea white paper focused on advanced chemistry, manufacturing, and controls strategies for the development and commercialization of cell and gene therapies. The white paper examines critical CMC considerations across CGT manufacturing, viral vector production, analytical method development, potency assays, process characterization, GMP manufacturing, quality systems, regulatory readiness, manufacturing scalability, and commercialization planning for advanced therapy medicinal products. It also highlights operational, analytical, and regulatory challenges associated with autologous and allogeneic cell therapies as well as gene therapy programs while outlining integrated CMC development approaches designed to improve product quality, manufacturing efficiency, regulatory compliance, technology transfer, and successful progression from clinical development through commercial manufacturing.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-26",
"dateModified": "2025-11-26",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-11/cmc-strategies-cell-gene-therapies.pdf",
"encodingFormat": "application/pdf"
}
}
]
}